Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.25, Implies 146% Upside

What happened

According to estimates from 8 analysts, Zevra Therapeutics' average price target rose from $25 to $25.25, with forecasts ranging from $20 to $35 per share. Based on the Oct. 30 closing price, the updated target implies about 146% potential upside.

Confirmed

Global impact / market context

A higher average target means analysts expect the share price to rise far more than the current price suggests. For a beginner, a price target is an analyst's estimate of where a stock may go, not a promise, so big upside signals optimism rather than certainty.

Analyst inference

The consensus rating remains Buy, with 9 Buys, 0 Holds and 0 Sells across the covering analysts. That split suggests the analyst community sees more potential reward than risk in Zevra shares, though a price target is an estimate, not a guarantee.

Analyst inference

What to watch

1. The average target moved only slightly, from $25 to $25.25, while individual forecasts range widely from $20 to $35. That wide spread shows analysts disagree about how much upside is realistic. Confirmed
2. Watch whether analysts change their ratings or targets after new company updates, since a Buy rating with no Holds or Sells leaves little room for downgrades if expectations disappoint. Proposed
3. Track the gap between the current share price and the $25.25 target; if the price rises toward it, the implied 146% upside shrinks and investor positioning may shift. Analyst inference

Evidence

• Original source link unavailable